The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1101
April 2, 2001
View Complete Issue         Table of Contents 2019 
Detrol LA and Ditropan XL
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Detrol LA and Ditropan XL
April 2, 2001 (Issue: 1101)
Direct-to-consumer advertisements are promoting the effectiveness of extended-release formulations of tolterodine tartrate (Detrol LA) and oxybutynin (Ditropan XL) for treatment of overactive bladder.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Detrol LA and Ditropan XL
Article code: 1101b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.